Biodesix, Inc

Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services. Its core business combines blood-based clinical tests for physicians with contract development, testing, and consulting services for biopharmaceutical, life sciences, and academic customers. The company uses multi-omic methods, including genomics, proteomics, radiomics, and AI, to develop and commercialize tests that address immediate clinical questions. Revenue is split between Lung Diagnostic Testing and Development Services, with clinical testing as the larger and more established business.

−25,1 %

−39,8 %

+24,1 %

1.86

1.86

— Biodesix, Inc
%
Lung Diagnostic Testing84% Blood-based diagnostic tests used by healthcare providers to assess lung nodules and related clinical questions.
Development Services16% Custom diagnostic development, testing, and consulting services for biopharma, life sciences, and research partners.

Biodesix sells primarily to healthcare providers and clinicians who order lung diagnostic tests for patients with...

  • Healthcare providers and cliniciansprimary

    Order blood-based lung diagnostic tests to help assess pulmonary nodules and improve patient management decisions.

  • Biopharmaceutical companiesprimary

    Buy development services, clinical trial sample testing, and biomarker/companion diagnostic support to advance drug and diagnostic programs.

  • Life sciences and diagnostic companiessecondary

    Use Biodesix for assay development, validation, and commercialization support when they need specialized diagnostic capabilities.

  • Academic and research institutionssecondary

    Engage the company for translational research, custom testing, and collaborative discovery work.

  • Payers and reimbursement ecosystemsecondary

    Not direct buyers in the usual sense, but critical to test adoption because coverage and reimbursement determine access and realized revenue.

Biodesix is headquartered in the United States and its commercial business is centered on the U.S. healthcare market...

  • •Headquartered in the United States
  • •Clinical testing revenue is primarily tied to U.S. physicians and payers
  • •Development Services are marketed to U.S. and international customers
  • •Medicare and Medicaid policy are important to revenue realization
  • •No country-level revenue split was disclosed in the excerpts
  • •U.S. regulatory and reimbursement changes can affect adoption and collections

Biodesix is focused on expanding adoption of its lung diagnostic tests by increasing clinical evidence, reimbursement...

01
Expand lung test adoption and reimbursementshort-term

Clinical volume and payer coverage directly drive realized revenue and determine whether the core testing business can scale.

02
Improve operating efficiency and gross marginshort-term

Higher test volume only creates durable value if the company can lower cost per test and convert scale into operating leverage.

03
Grow Development Services and strategic partnershipsmedium-term

Biopharma and research relationships diversify revenue and can create longer-term opportunities in companion diagnostics and discovery.

Biodesix depends heavily on payer coverage, reimbursement decisions, and physician adoption, so any slowdown in market...

high

Coverage and reimbursement uncertainty

Diagnostic revenue depends on payer decisions, and the company recognizes lung test revenue using estimates of amounts ultimately collectible.

Scope
Lung Diagnostic Testing
Materiality
high
high

Dependence on Medicare, Medicaid, and federal healthcare programs

A prolonged government shutdown or policy change could delay payments, coverage decisions, or patient access.

Scope
U.S. clinical testing revenue
Materiality
high
high

Commercial adoption risk

Revenue growth depends on physicians, payers, and patients accepting the clinical utility of the tests.

Scope
Nodify Lung and other diagnostic tests
Materiality
high
medium

Biopharma customer retention and expansion

Development Services growth depends on maintaining and expanding relationships with existing customers and winning new ones.

Scope
Development Services
Materiality
medium
medium

Supply chain and single-source supplier dependence

Laboratory testing operations can be disrupted by shortages, price increases, or vendor failures.

Scope
Testing operations and specimen logistics
Materiality
medium
medium

Nasdaq listing compliance

Failure to maintain minimum bid price or other listing standards could affect market access and investor confidence.

Scope
Capital markets access
Materiality
medium
Revenue recognition for lung diagnostic tests
Can materially affect reported revenue, receivables, and margins
ASC 606 contract accounting for Development Services
Can shift revenue between quarters
Variable consideration and collection estimates
Affects revenue, bad debt-like adjustments, and comparability
Share-based compensation
Affects operating expense and net loss

BIODESIX INC

BDSX · Services-Medical Laboratories

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

BIOTRICITY INC.

BTCY · Surgical & Medical Instruments & Apparatus

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

: 11/08/2026